CorMedix Inc (NASDAQ:CRMD) — Market Cap & Net Worth
Market Cap & Net Worth: CorMedix Inc (CRMD)
CorMedix Inc (NASDAQ:CRMD) has a market capitalization of $597.22 Million ($597.22 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11631 globally and #2786 in its home market, demonstrating a 6.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CorMedix Inc's stock price $7.79 by its total outstanding shares 78789045 (78.79 Million). Analyse CorMedix Inc cash conversion from operations to see how efficiently the company converts income to cash.
CorMedix Inc Market Cap History: 2015 to 2026
CorMedix Inc's market capitalization history from 2015 to 2026. Data shows change from $799.71 Million to $613.77 Million (-4.05% CAGR).
Index Memberships
CorMedix Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #303 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1121 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.04% | #175 of 263 |
Weight: CorMedix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CorMedix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CorMedix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.68x
CorMedix Inc's market cap is 14.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $799.71 Million | $210.13K | -$18.19 Million | 3805.78x | N/A |
| 2016 | $602.74 Million | $224.10K | -$24.64 Million | 2689.53x | N/A |
| 2017 | $197.76 Million | $329.33K | -$33.01 Million | 600.50x | N/A |
| 2018 | $508.19 Million | $429.80K | -$26.83 Million | 1182.39x | N/A |
| 2019 | $573.58 Million | $283.27K | -$16.43 Million | 2024.90x | N/A |
| 2020 | $585.40 Million | $239.23K | -$22.03 Million | 2447.02x | N/A |
| 2021 | $358.49 Million | $190.94K | -$28.21 Million | 1877.54x | N/A |
| 2022 | $332.49 Million | $65.41K | -$29.70 Million | 5083.32x | N/A |
| 2024 | $638.19 Million | $43.47 Million | -$17.93 Million | 14.68x | N/A |
Competitor Companies of CRMD by Market Capitalization
Companies near CorMedix Inc in the global market cap rankings as of May 4, 2026.
Key companies related to CorMedix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CorMedix Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, CorMedix Inc's market cap moved from $799.71 Million to $ 613.77 Million, with a yearly change of -4.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $613.77 Million | -33.02% |
| 2025 | $916.32 Million | +43.58% |
| 2024 | $638.19 Million | +115.43% |
| 2023 | $296.25 Million | -10.90% |
| 2022 | $332.49 Million | -7.25% |
| 2021 | $358.49 Million | -38.76% |
| 2020 | $585.40 Million | +2.06% |
| 2019 | $573.58 Million | +12.87% |
| 2018 | $508.19 Million | +156.97% |
| 2017 | $197.76 Million | -67.19% |
| 2016 | $602.74 Million | -24.63% |
| 2015 | $799.71 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of CorMedix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $597.22 Million USD |
| MoneyControl | $597.22 Million USD |
| MarketWatch | $597.22 Million USD |
| marketcap.company | $597.22 Million USD |
| Reuters | $597.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more